Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04898023 · ClinicalTrials.gov registry record · Phase 2
Zinc and Green Tea Extract for Community Respiratory Viral Infections
A Phase 2 study, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04898023 is a Phase 2 study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 17 participants.
The verdict
NCT04898023, a Phase 2 study, was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Zinc and green tea supplementation have both been independently studied for supporting immune health during cold and flu-like illness in non-hospitalized patients with clinical trials demonstrating promising but inconsistent results. Combination therapy may offer an improved effect as the antioxidant compounds found in green tea have been shown to increase cellular zinc concentrations thereby inhibiting viral replication. This study seeks to evaluate the effect of combination supplementation using established doses of zinc and green tea extract on symptom duration and severity from cold and flu-like illness, including COVID-19, in adult community patients enrolled in a randomized placebo-controlled trial.
Interventions
- DRUG Placebo
- DRUG zinc-green tea extract-ascorbic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-09-21 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04898023
The ClinicalTrials.gov registry entry for NCT04898023 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04898023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04898023 about?
NCT04898023 is a clinical study titled "Zinc and Green Tea Extract for Community Respiratory Viral Infections". Zinc and green tea supplementation have both been independently studied for supporting immune health during cold and flu-like illness in non-hospitalized patients with clinical trials demonstrating promising but inconsistent results. Combination therapy may offer an improved effect as the antioxidan...
What is the current status of trial NCT04898023?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2022-09-21. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT04898023?
The interventions under investigation include: Placebo (DRUG), zinc-green tea extract-ascorbic acid (DRUG).
Who is sponsoring clinical trial NCT04898023?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.